Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2731-2737

  Pritchard, K I ^a   Paterson, A H ^a   Paul, N A ^a   Zee, B ^a   Fine, S ^a   Pater, J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0029783365     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2731     Document Type: Article

References (42)

1. Trousseau A: Phlegmasia alba dolens, in Lectures in Clinical Medicine, Delivered at the Hotel-Dieu, Paris, vol 3. London, United Kingdom, New Syndenham Society, 1865, p 94
2. Sack GH Jr, Levin J, Bell WR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56:1-37, 1977
3. Pradoni P, Lensing AWA, Buller HR, et al: Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133, 1992
4. Doll DC, Yarbro JW: Vascular toxicity associated with antineoplastic agents. Semin Oncol 19:580-596, 1992
5. Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887-889, 1984
6. Cutuli BF, Petit JC, Fricker JP, et al: Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: Occurrence of thromboembolic complications. Oncol Rep 1:59-63, 1994
7. Nevasaari K, Heikkinen M, Taskinen P: Tamoxifen and thrombosis. Lancet 2:946-947, 1978
8. Hendrick A, Subramanian VP: Tamoxifen and thromboembolism. JAMA 243:514-515, 1980
9. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85:1398-1406, 1993
10. Fisher B, Constantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320:479-484, 1989
11. Goodnough LT, Saito H, Manni A, et al: Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 54:1264-1268, 1984
12. Levine M, Hirsh J, Gent M, et al: Double-blind randomised trial of very low dose Warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889, 1994
13. Weiss RB, Tormey DC, Holland JF, et al: Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 65:677-679, 1981
14. Wall JG, Weiss RB, Norton L, et al: Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A Cancer and Leukemia Group B study. Am J Med 87:501-504, 1989
15. Clahsen PC, van de Velde CJH, Julien JP, et al: Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: A European Organization for Research and Treatment of Cancer Breast Cancer cooperative group study. J Clin Oncol 12:1266-1271, 1994
16. Levine MN, Gent M, Hirsh J, et al: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404-407, 1988
17. Saphner T, Tormey DC, Gray R: Venous and arterial throm- bosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294, 1991
18. Healey B, Tormey DC, Gray R, et al: Arterial and venous thrombotic events in ECOG adjuvant breast cancer trials. Proc Am Soc Clin Oncol 6:208, 1987 (abstr)
19. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582,1989
20. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018,1990
21. Pritchard KI, Pater J, Paul N, et al: Thromboembolic complications related to chemotherapy in a National Institute of Canada randomized trial of tamoxifen versus tamoxifen plus chemotherapy in postmenopausal women with axillary node positive receptor positive breast cancer. Proc Am Soc Clin Oncol 8:25, 1989 (abstr)
22. Mehta C, Patel N: Statistical Account User Manual. CYTEL Software, Cambridge, MA, 1991
23. Fleiss JL: Statistical Methods for Rates and Proportions (ed 2). New York, NY, Wiley, 1981, pp 19-32
24. Kaufman M, Lammers G, Fritze D, et al: Adjuvant chemotherapy and venous thrombosis. J Cancer Res Clin Oncol 104:195-196, 1982
25. Mohapatro SK, Dandapat MC, Padhi NC: Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. J Ind Med Assoc 90:39-42, 1990
26. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 9:295-304, 1991
27. Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: Effects on sex hormone binding globulin and antithrombin III. Cancer Res 47:4517-4519, 1987
28. Aranda A, Ṕaramo JA, Cuesto B, et al: Fibrinolytic activity in malignancy. Thromb Haemost 58:1 10, 1987 (abstr)
29. Ruiz MA, Marugán I, Estellés P, et al: The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patients. Cancer 63:643-648, 1989
30. Jones AL, Powles TJ, Treleaven JG, et al: Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 66:744-747, 1992
31. Canobbio L, Fassio T, Ardizzoni A, et al: Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 58:1032-1036, 1986
32. Nicholson GL, Custead SE: Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 45:331-336, 1983
33. Bertomeu MC, Gallo S, Lauri D, et al: Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 8:511-518, 1990
34. Licciardello J, Moake J, Rudy C, et al: Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42:296-300, 1985
35. Rogers JS, Murgo AJ, Fontana JA, et al: Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6:276-281, 1988
36. Pritchard KI, Paterson AHG, Fine S, et al: A randomized trial of CMF chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive (tve) estrogen (ER) and/ or progesterone receptor (PgR) tve breast cancer. Proc Am Soc Clin Oncol 11:60, 1992 (abstr)
37. Pritchard KI, Zee B, Paul N, et al: CMF added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive (tve) estrogen (ER) and/or progesterone receptor (PgR) tve breast cancer, negative results from a randomized clinical trial. Proc Am Soc Clin Oncol 13:65, 1994 (abstr)
38. Goldhirsch A, Gelber RD, Castiglione M: Adjuvant therapy of breast cancer. Eur J Cancer 27:389-399, 1991
39. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al: The International (Ludwig) Breast Cancer Study Group trials I-IV: 15 years follow-up. Ann Oncol 5:717-24, 1994
40. Mouridsen HT, Rose C, Overguard M, et al: Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DRCG 77 C and DBCG 82 C. Acta Oncol 27:679-705, 1988
41. Boccardo F, Rubagotti A, Amoroso D, et al: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemohormone Therapy Co-operative Group) trial. Eur J Cancer 28:673-680, 1992
42. Rivkin SE, Green S, Metch B, et al: Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients. A. Southwest Oncology Group study. J Clin Oncol 12:2078-2085, 1994